Amicus Therapeutics, Inc.
3675 Market Street
Philadelphia
Pennsylvania
19104
United States
Website: http://www.amicusrx.com/
Email: info@amicusrx.com
About Amicus Therapeutics, Inc.
Amicus Therapeutics is a global biotechnology company at the forefront of therapies for rare and orphan diseases. We have a unique set of platform technologies and medicines in development for people living with rare and devastating diseases, including the Lysosomal Storage Disorders Fabry disease and Pompe disease, as well as the genetic connective skin disorder Epidermolysis Bullosa (EB).
The needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. Our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers.
366 articles with Amicus Therapeutics, Inc.
-
Amicus announced that it is halting its CLN6 Batten disease gene therapy program after studies failed to achieve consistent results.
-
Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance
1/10/2022
Amicus Therapeutics, a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, provided its preliminary and unaudited 2021 revenue, corporate updates, and full-year 2022 outlook and revenue guidance.
-
Amicus Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
Amicus Therapeutics (Nasdaq: FOLD) today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually on Wednesday, January 12, 2022 at 3:45 p.m. E.T.
-
European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease
12/3/2021
Amicus Therapeutics (Nasdaq: FOLD) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Applications (MAA) for AT-GAA .
-
Amicus Therapeutics to Present at the 4th Annual Evercore ISI HealthCONx Virtual Conference
11/24/2021
Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 1, 2021 at 8:50 a.m. E.T.
-
Clinical Catch-Up: November 15-19
11/22/2021
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look. -
Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism
11/22/2021
Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) being held virtually and in Sydney, Australia, November 21-23, 2021.
-
The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease
11/18/2021
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, announced today that the data from the Phase 3 PROPEL pivotal trial, assessing the efficacy, safety and tolerability of AT-GAA in adults with late-onset Pompe disease compared to the standard of care, alglucosidase alfa, were published online in The Lancet Neurology.
-
Amicus Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
11/11/2021
Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 8:00 a.m. E.T.
-
Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates
11/9/2021
Amicus Therapeutics today announced financial results for the quarter ended September 30, 2021.
-
Amicus Therapeutics to Announce Third Quarter 2021 Financial Results on November 9, 2021
11/3/2021
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 9, 2021 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2021.
-
As the city rapidly develops as a biopharma hub, wet lab space is rapidly dwindling.
-
U.S. FDA Accepts Filings for Amicus’ AT-GAA for the Treatment of Pompe Disease
9/29/2021
Amicus Therapeutics announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for cipaglucosidase alfa and the New Drug Application for miglustat for AT-GAA, the Company’s investigational two-component therapy for the treatment of Pompe disease.
-
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”
9/29/2021
Amicus Therapeutics, Inc. announced its intent to launch a next-generation genetic medicine company, Caritas Therapeutics, Inc., through a definitive business combination agreement pursuant to which the Amicus gene therapy business will be acquired by ARYA Sciences Acquisition Corp IV, a special purpose acquisition company or SPAC, sponsored by Perceptive Advisors.
-
Amicus Therapeutics is launching a next-generation genetic medicine company called Caritas Therapeutics, Inc. through a merger deal with ARYA Sciences Acquisition Corp IV.
-
Amicus Therapeutics Announces Presentations at the 26th International Annual Congress of the World Muscle Society
9/20/2021
Amicus Therapeutics, announced two posters for presentation highlighting its development program for Pompe disease at the 26th International Annual Congress of the World Muscle Society being held virtually, September 20-24, 2021.
-
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2021
9/3/2021
Amicus Therapeutics announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September:
-
Amicus Therapeutics Announces Second Quarter 2021 Financial Results and Corporate Updates
8/5/2021
Amicus Therapeutics, a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, announced financial results for the quarter ended June 30, 2021.
-
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference - Aug 04, 2021
8/4/2021
Amicus Therapeutics announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 9:00 a.m. E.T.
-
Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease
8/2/2021
Amicus Therapeutics, a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, announced the European Commission has approved Galafold® for use in adolescents aged 12 to <16 years weighing ≥ 45 kg with a confirmed diagnosis of Fabry disease and who have an amenable mutation.